FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs

Cancer Immunology, Immunotherapy

Volumn 62, Issue 5, 2013, Pages 941-948

  White, Ann L ^a   Chan, H T Claude ^a   French, Ruth R ^a   Beers, Stephen A ^a   Cragg, Mark S ^a   Johnson, Peter W M ^a   Glennie, Martin J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti CD40; Cancer therapy; CIMT 2012; Immunomodulatory; Isotype

Indexed keywords

ALEMTUZUMAB; BMS 936959; CD27 ANTIBODY; CD40 ANTIBODY; CP 870893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DROZITUMAB; FAS ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; NIVOLUMAB; OX40 ANTIBODY; PD1 ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; APOPTOSIS; BINDING AFFINITY; BONE MARROW CELL; CELL ACTIVATION; CELL KILLING; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING; DRUG CYTOTOXICITY; DRUG POTENCY; EFFECTOR CELL; HUMAN; KIDNEY CANCER; LUNG CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TARGET CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; APOPTOSIS; HUMANS; IMMUNOGLOBULIN G; MICE; NEOPLASMS; PROTEIN BINDING; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 84877822833     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1398-6     Document Type: Review

References (58)

1. Peggs KS, Quezada SA, Allison JP (2009) Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x
2. Pardoll D, Drake C (2012) Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209(2):201-209. doi: 10.1084/jem.20112275
3. Mellman I, Coukos G, Dranoff G (2012) Cancer immunotherapy comes of age. Nature 480(7378):480-489. doi: 10.1038/nature10673
4. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612-1616. doi: 10.1126/science.1198443
5. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723. doi: 10.1056/NEJMoa1003466
6. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454. doi: 10.1056/NEJMoa1200690
7. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465. doi: 0.1056/NEJMoa1200694
8. Yuan J, Adamow M, Ginsberg BA et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci 108(40):16723-16728. doi: 10.1073/pnas.1110814108
9. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS (2009) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95(1):135-143. doi: 10.3324/haematol.2008.001628
10. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51. doi: 10.1056/NEJMra043186
11. Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26(5 Suppl 14):52-57
12. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327. doi: 10.1038/nri2744
13. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073-1078. doi: 10.1038/nbt0905-1073
14. Nimmerjahn F, Ravetch JV (2012) Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12:13-19
15. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1):34-47. doi: 10.1038/nri2206
16. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199(12):1659-1669. doi: 10.1084/jem.20040119
17. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF (2008) Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112(4):1205-1213. doi: 10.1182/blood-2008-01-135160
18. Beers SA, French RR, Chan HT et al (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115(25):5191-5201. doi: 10.1182/blood-2010-01-263533
19. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF (2006) Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203(3):743-753. doi: 10.1084/jem.20052283
20. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512. doi: 10.1126/science.1118948
21. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3):754-758
22. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947. doi: 10.1200/JCO.2003.05.013
23. Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27(7):1122-1129. doi: 10.1200/JCO.2008.18.0463
24. Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789-1796. doi: 10.1200/JCO.2007.14.8957
25. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6(4):443-446. doi: 10.1038/74704
26. Lim SH, Vaughan AT, Ashton-Key M et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118(9):2530-2540. doi: 10.1182/blood-2011-01-330357
27. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12(21-22):898-910. doi: 10.1016/j.drudis.2007.08. 009
28. van Kooten C, Banchereau J (2000) CD40-CD40 ligand. J Leukoc Biol 67(1):2-17
29. Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111-135. doi: 10.1146/annurev.immunol.16.1.111
30. Eliopoulos AG, Young LS (2004) The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4(4):360-367. doi: 10.1016/j.coph.2004.02.008
31. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5(5):548-553. doi: 10.1038/8426
32. Vonderheide RH (2007) Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 13(4):1083-1088. doi: 10.1158/1078-0432.CCR-06-1893
33. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168(6):2720-2728
34. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG, Glennie MJ (2001) CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 248(1-2):139-147. doi: S0022175900003495
35. Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876-883. doi: 10.1200/JCO.2006.08.3311
36. Advani R, Forero-Torres A, Furman RR et al (2009) Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 27(26):4371-4377. doi: 10.1200/JCO.2008.21. 3017
37. Luqman M, Klabunde S, Lin K et al (2008) The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112(3):711-720. doi: 10.1182/blood-2007-04-084756
38. Kasran A, Boon L, Wortel CH et al (2005) Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 22(2):111-122. doi: 10.1111/j.1365-2036. 2005.02526.x
39. Johnson PW, Steve NM, Chowdhury F, Dobbyn J, Hall E, Ashton-Key M, Hodges E, Ottensmeier CH, Williams A, Glennie M (2010) A cancer research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. J Clin Oncol 28(Suppl; abstract 2507)
40. Hussein M, Berenson JR, Niesvizky R et al (2010) A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5):845-848. doi: 10.3324/haematol.2009.008003
41. Klaus GG, Holman M, Hasbold J (1994) Properties of mouse CD40: the role of homotypic adhesion in the activation of B cells via CD40. Eur J Immunol 24(11):2714-2719. doi: 10.1002/eji.1830241248
42. White AL, Chan HT, Roghanian A et al (2011) Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187(4):1754-1763. doi: 10.4049/jimmunol.1101135
43. Li F, Ravetch JV (2011) Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333(6045):1030-1034. doi: 10.1126/science.1206954
44. Smith KG, Clatworthy MR (2010) FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 10(5):328-343. doi: 10.1038/nri2762
45. Yamamoto M, Sato S, Hemmi H et al (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640-643. doi: 10.1126/science.1087262
46. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 171(2):562-568
47. Li F, Ravetch JV (2012) Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci 109(27):10966-10971. doi: 10.1073/pnas.1208698109
48. Wilson NS, Yang B, Yang A et al (2011) An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19(1):101-113. doi: 10.1016/j.ccr.2010.11.012
49. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23(1):41-51. doi: 10.1016/j.immuni.2005.05.010
50. Kornbluth RS, Stempniak M, Stone GW (2012) Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol 31(4):279-288. doi: 10(3109/08830185),2012,703272
51. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166(8):4891-4898
52. Takeda K, Yamaguchi N, Akiba H et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199(4):437-448. doi: 10.1084/jem.20031457
53. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113(16):3716-3725. doi: 10.1182/blood-2008-09-179754
54. Chu SY, Vostiar I, Karki S et al (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 45(15):3926-3933. doi: 10.1016/j.molimm.2008.06.027
55. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV (2012) Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci 109(16):6181-6186. doi: 10.1073/pnas.1203954109
56. Pound JD, Challa A, Holder MJ et al (1999) Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int Immunol 11(1):11-20
57. Luhder F, Huang Y, Dennehy KM et al (2003) Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197(8):955-966. doi: 10.1084/jem.20021024
58. Niederfellner G, Lammens A, Mundigl O et al (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 118(2):358-367. doi: 10.1182/blood-2010-09-305847